Nanobiotix Updates Share Capital and Voting Rights as of March 31, 2026

The latest announcement is out from Nanobiotix ( (NBTX) ).

On April 7, 2026, Nanobiotix reported its share capital and voting rights position as of March 31, 2026, in line with French regulatory requirements for listed companies. The disclosure showed 48,517,630 shares outstanding, with 50,165,132 theoretical voting rights and 50,143,014 exercisable voting rights, offering investors updated transparency on the company’s capital structure across its Euronext Paris and Nasdaq listings.

This routine monthly update helps shareholders and market participants track threshold crossings, free float dynamics, and potential dilution over time. By clearly distinguishing between gross and net voting rights, Nanobiotix supports informed decision-making by investors and reinforces its compliance posture in both French and U.S. markets.

The most recent analyst rating on (NBTX) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.

Spark’s Take on NBTX Stock

According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.

The score is held back mainly by weak financial fundamentals—ongoing losses, consistent cash burn, and balance-sheet pressure from negative equity and higher debt. Offsetting this, technicals are relatively strong with an upward trend and positive MACD, while the latest earnings update was constructive on liquidity/runway and clinical progress but tempered by one-off revenue effects and dependency on J&J-controlled timelines.

To see Spark’s full report on NBTX stock, click here.

More about Nanobiotix

Nanobiotix S.A. is a late-stage clinical biotechnology company headquartered in Paris, France, focused on physics-based nanotechnology platforms aimed at improving treatment outcomes in oncology, bioavailability and biodistribution, and central nervous system disorders. Founded in 2003, the company holds more than 30 patent families and is dual-listed on Euronext Paris and the Nasdaq Global Select Market, with an additional subsidiary in Cambridge, Massachusetts.

Its lead activity centers on developing disruptive therapeutic approaches using nanotechnology to address unmet medical needs, targeting millions of patients worldwide. By leveraging multiple proprietary platforms and a global capital markets presence in Europe and the U.S., Nanobiotix positions itself as an innovation-driven player in late-stage clinical biotech, seeking to expand its footprint in oncology and related advanced therapeutics.

Average Trading Volume: 45,084

Technical Sentiment Signal: Buy

Current Market Cap: $1.53B

For a thorough assessment of NBTX stock, go to TipRanks’ Stock Analysis page.